Network point-of-care glucose testing refers to systems in which glucose testing devices are connected through a network, enabling real-time data sharing between healthcare providers and patients. These systems integrate with electronic health records to give immediate access to blood glucose readings and support clinical decision-making. According to Polaris Market Research, the Network Point-Of-Care Glucose Testing market was valued at USD 1,387.65 million in 2024 and USD 1,443.85 million in 2025, and is projected to reach USD 2,109.01 million by 2034 at a CAGR of 4.3%. North America led in 2024.
The market is driven by the rising prevalence of diabetes, increasing demand for rapid and accurate glucose monitoring and advancements in connectivity solutions, serving hospitals, clinics and home care settings.
Diabetes Prevalence and Sensor Innovation
The rising incidence of diabetes is a central demand driver. According to the International Diabetes Federation, approximately 537 million adults had diabetes in 2021, and the number is projected to rise to 643 million by 2030. This increases demand for efficient, accessible monitoring. Continuous glucose monitors that provide real-time data and integrate with other health devices are encouraging adoption, and Abbott's Lingo and Dexcom's Stelo are over-the-counter options designed for individuals not on insulin therapy. In June 2024, Abbott obtained FDA clearance for two over-the-counter devices, Libre Rio and Lingo. Libre Rio is designed for type 2 diabetes patients who do not use insulin, while Lingo monitors glucose levels and offers personalized insights. This surge highlights the escalating demand for solutions that manage and mitigate diabetes-related health complications.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/network-point-of-care-glucose-testing-market
Remote Care and Connected Workflows
The shift toward remote patient monitoring is another significant driver. It lets healthcare providers track patient health data in real time, supporting timely interventions and personalized care plans, and it reduces the burden on healthcare facilities by minimizing in-person visits. Integrating networked glucose testing devices into such systems gives patients and providers efficient tools for managing diabetes remotely. The report also highlights AI-powered predictive analytics as a growing trend that helps in early diagnosis and better glucose level management. Connectivity with mobile applications also improves data accessibility and patient management.
Product and Modality Leaders
By product, the Accu-Chek Inform II segment held the largest share in 2024 because healthcare professionals widely use it for blood glucose monitoring across capillary, venous, neonatal, arterial and whole blood samples. By modality, wearable devices were dominant in 2024 on the back of user-friendly design and continuous monitoring capabilities, with real-time data transmission that helps patients and providers manage blood glucose more effectively. In North America, the presence of major players such as Abbott, Nova Biomedical and Prodigy Diabetes Care, along with higher government spending on diabetes management, supports the region's leading share. High device costs may act as a restraint on market growth. Abbott Laboratories, established in 1888, is a diversified healthcare company that develops diagnostics products, medical devices, nutritionals and branded generic pharmaceuticals. F. Hoffmann-La Roche, founded in 1896, is a biotechnology company and in-vitro diagnostics provider that also offers diabetes management solutions.
Key Players in the Network Point-Of-Care Glucose Testing Market
Abbott Laboratories offers the FreeStyle Libre system for continuous monitoring, and the market features a broad group of participants. Key players include:
- ACON Laboratories, Inc.
- Abbott Laboratories
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- Danaher Corporation (HemoCue subsidiary)
- DexCom, Inc.
- EKF Diagnostics Holdings plc.
- Hoffmann-La Roche Ltd.
- LifeScan, Inc. (Platinum Equity Advisors, LLC subsidiary)
- Medtronic plc
- Nipro Corporation Japan
- Nova Biomedical Corporation
- Prodigy Diabetes Care, LLC
- Terumo Corporation
- Trividia Health, Inc.
Conclusion
Rising diabetes prevalence, sensor innovation and the shift toward remote care are steadily lifting the Network Point-Of-Care Glucose Testing market toward USD 2,109.01 million by 2034. Vendors that combine accurate testing with seamless connectivity, while managing device costs, are positioned to meet demand across hospitals, clinics and home care settings.
More Trending Latest Reports By Polaris Market Research:
Gynecological Examination Chairs Market
Enterprise Content Management Market
AI Trust, Risk and Security Management Market